<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to the adult patient with an incidental solid liver lesion</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to the adult patient with an incidental solid liver lesion</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Approach to the adult patient with an incidental solid liver lesion</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan M Schwartz, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan B Kruskal, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjiv Chopra, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 29, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Liver lesions may be detected on imaging studies performed for an unrelated reason (ie, incidental liver lesion). The approach in this topic applies to liver lesions found incidentally in adult patients without signs or symptoms (eg, right upper quadrant pain) attributable to the lesion and without risk factors for hepatic malignancy. Separate strategies and individual adjustments are needed for high-risk populations including patients with any of the following risk factors [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cirrhosis </p><p class="bulletIndent1"><span class="glyph">●</span>Chronic hepatitis B virus infection without cirrhosis</p><p class="bulletIndent1"><span class="glyph">●</span>History of malignancy with propensity to metastasize to the liver</p><p></p><p>The approach to patients with suspected hepatocellular carcinoma (HCC) and indications for HCC surveillance are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma"</a> and  <a class="medical medical_review" href="/z/d/html/3583.html" rel="external">"Surveillance for hepatocellular carcinoma in adults"</a>.)</p><p>The approach to patients with a liver lesion that is predominantly cystic is presented separately. (See  <a class="medical medical_review" href="/z/d/html/3588.html" rel="external">"Diagnosis and management of cystic lesions of the liver"</a>.)</p><p>The evaluation and management of patients with liver abscess is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2680.html" rel="external">"Pyogenic liver abscess"</a> and  <a class="medical medical_review" href="/z/d/html/5728.html" rel="external">"Extraintestinal Entamoeba histolytica amebiasis"</a>.)</p><p class="headingAnchor" id="H3032591439"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>Technologic advances in imaging such as computed tomography (CT) and magnetic resonance imaging and their widespread use have led to detection of many incidental findings [<a href="#rid2">2</a>]. For example, in a study including over 17,000 individuals who underwent screening chest CT, the prevalence rate of incidental hepatobiliary findings was 6 percent [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H155745288"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The etiology of incidental liver lesions can be categorized as benign or malignant. While most incidental lesions occur as a focal finding, multiple lesions may be seen in some patients (eg, those with more than one hepatic hemangioma). </p><p class="headingAnchor" id="H3978859860"><span class="h2">Benign lesions</span><span class="headingEndMark"> — </span>Benign liver lesions that may be found incidentally include [<a href="#rid4">4</a>] (see <a class="local">'Lesion characteristics'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatic hemangioma</strong> – Hepatic hemangiomas (also referred to as cavernous hemangiomas because of the cavernous vascular space seen histologically) are the most common benign liver lesion. Hepatic hemangioma can be diagnosed at any age; however, the majority of lesions (up to 80 percent) are diagnosed in patients who are between the ages of 30 and 50 years. In adults, hemangiomas occur more frequently in females with a ratio of approximately 3:1 [<a href="#rid5">5,6</a>]. The lesion is most often solitary but multiple hemangiomas may be present. Most patients with hepatic hemangioma are asymptomatic and have an excellent prognosis. (See  <a class="medical medical_review" href="/z/d/html/3594.html" rel="external">"Hepatic hemangioma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Focal nodular hyperplasia</strong> – Focal nodular hyperplasia (FNH) is a benign liver lesion that is composed of a proliferation of hyperplastic hepatocytes surrounding a central stellate scar. Typically, FNH is a solitary lesion that is more commonly seen in women [<a href="#rid7">7-9</a>]. </p><p></p><p class="bulletIndent1">There is increasing recognition of FNH among patients undergoing abdominal imaging for other reasons. In a large observational series including patients referred for ultrasound or contrast-enhanced computed tomography (CT), the prevalence of FNH was 0.2 percent and 1.6 percent, respectively [<a href="#rid10">10,11</a>]. (See  <a class="medical medical_review" href="/z/d/html/3577.html" rel="external">"Focal nodular hyperplasia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatocellular adenoma</strong> – Hepatocellular adenoma (HCA) (also termed hepatic adenoma) is an uncommon solid, benign liver lesion that develops in an otherwise normal-appearing liver. Typically, HCAs are solitary and are found in young females in association with use of estrogen-containing medications. In addition, patients with glycogen storage disease or metabolic syndrome are at higher risk for developing HCA  (<a class="graphic graphic_diagnosticimage graphicRef66984" href="/z/d/graphic/66984.html" rel="external">image 1</a>). (See  <a class="medical medical_review" href="/z/d/html/3590.html" rel="external">"Hepatocellular adenoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regenerative nodules</strong> – Regenerative nodules develop in response to liver injury and are comprised of a proliferation of hepatocytes and surrounding stroma. They are typically seen in the setting of cirrhosis [<a href="#rid12">12,13</a>]. </p><p></p><p class="headingAnchor" id="H655490923"><span class="h2">Malignant lesions</span><span class="headingEndMark"> — </span>Malignant liver lesions that may be found incidentally include [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatocellular carcinoma</strong> – Hepatocellular carcinoma is a primary tumor of the liver that develops in the setting of chronic liver disease, particularly in patients with cirrhosis of any cause or chronic hepatitis B virus infection  (<a class="graphic graphic_diagnosticimage graphicRef75007" href="/z/d/graphic/75007.html" rel="external">image 2</a>). (See  <a class="medical medical_review" href="/z/d/html/3599.html" rel="external">"Epidemiology and risk factors for hepatocellular carcinoma"</a>.)</p><p></p><p class="bulletIndent1">The diagnosis of HCC can be made with dynamic contrast enhanced CT or MRI tailored for liver lesion evaluation in patients at risk for HCC. (See  <a class="medical medical_review" href="/z/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cholangiocarcinoma</strong> – Cholangiocarcinomas (bile duct cancers) arise from the epithelial cells of the intrahepatic ducts and extrahepatic bile ducts, and may be found incidentally during the early stage of disease. A number of risk factors for cholangiocarcinoma have been recognized. In the United States and Europe, the main risk factors are primary sclerosing cholangitis and fibropolycystic liver disease (eg, choledochal cysts), while hepatolithiasis (also called recurrent pyogenic cholangitis) is commonly associated with cholangiocarcinoma in Asia. (See  <a class="medical medical_review" href="/z/d/html/663.html" rel="external">"Epidemiology, risk factors, anatomy, and pathology of cholangiocarcinoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metastatic disease</strong> – The liver is a common site for metastasis from solid tumors, and patients with a history of malignancy are at higher risk for metastatic disease [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">"Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">DIAGNOSTIC APPROACH</span></p><p class="headingAnchor" id="H122356664"><span class="h2">Factors that guide decision-making</span></p><p class="headingAnchor" id="H2366010389"><span class="h3">Assess risk factors for liver malignancy</span><span class="headingEndMark"> — </span>As a first step, it is important to confirm that the patient does not have risk factors for hepatocellular carcinoma (eg, cirrhosis, chronic hepatitis B infection) or for liver metastases (eg, history of extrahepatic malignancy)  (<a class="graphic graphic_algorithm graphicRef127404" href="/z/d/graphic/127404.html" rel="external">algorithm 1</a>). The diagnostic evaluation for patients who are at risk for developing a malignant liver lesion is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma"</a>.)</p><p>The clinical features and diagnosis of cirrhosis are presented separately. (See  <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2736199068"><span class="h3">Lesion characteristics</span><span class="headingEndMark"> — </span>For patients without risk factors for a malignant hepatic lesion, the initial diagnostic evaluation is primarily based on the imaging appearance of the incidental lesion. Some liver lesions (eg, hepatic hemangioma &lt;3 cm) can be diagnosed based on noncontrast ultrasound if imaging criteria are met, while other lesions require further diagnostic evaluation based on lesion characteristics (eg, lesion size, margins). (See  <a class="medical medical_review" href="/z/d/html/3594.html" rel="external">"Hepatic hemangioma", section on 'Diagnostic approach'</a>.)</p><p>The following lesion characteristics guide further imaging selection and management [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Size – Most incidental liver lesions &lt;1 cm are benign, while some small lesions may be difficult to definitively characterize by imaging methods [<a href="#rid15">15,16</a>]. Most lesions ≥1 cm can be diagnosed either by further imaging (eg, MRI tailored for liver lesion evaluation) and/or histology. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Margin – Benign lesions typically have smooth margins.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Enhancement pattern on contrast enhanced imaging –Most liver lesions have characteristic enhancement features  (<a class="graphic graphic_table graphicRef127122" href="/z/d/graphic/127122.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hepatic hemangioma – Hepatic hemangioma typically demonstrates peripheral nodular enhancement in the early phase, followed by a centripetal pattern or "filling in" during the late phase  (<a class="graphic graphic_diagnosticimage graphicRef70560" href="/z/d/graphic/70560.html" rel="external">image 3</a>). Peripheral nodular or globular enhancement representing venous lakes is seen in most hemangiomas &gt;4 cm in size [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/3594.html" rel="external">"Hepatic hemangioma", section on 'Imaging'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hepatocellular adenoma – On contrast-enhanced computed tomography (CT), hepatocellular adenoma may show peripheral enhancement that reflects the large subcapsular feeding vessels with a centripetal pattern of enhancement [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/3590.html" rel="external">"Hepatocellular adenoma", section on 'Imaging studies'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Focal nodular hyperplasia – Administration of a liver specific gadolinium-based magnetic resonance contrast agent produces rapid enhancement of focal nodular hyperplasia due to its arterial blood supply, resulting in a hyperintense lesion on early films. On delayed images, it becomes more isointense with respect to normal liver. The central scar enhances on delayed imaging as contrast gradually diffuses into the fibrous center of the mass  (<a class="graphic graphic_diagnosticimage graphicRef51338" href="/z/d/graphic/51338.html" rel="external">image 4</a> and <a class="graphic graphic_diagnosticimage graphicRef64152" href="/z/d/graphic/64152.html" rel="external">image 5</a>) [<a href="#rid19">19,20</a>]. (See  <a class="medical medical_review" href="/z/d/html/3577.html" rel="external">"Focal nodular hyperplasia", section on 'Imaging'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hepatocellular carcinoma – Hepatocellular carcinoma (HCC) typically demonstrates a non-rim arterial phase hyperenhancement relative to the liver parenchyma  (<a class="graphic graphic_table graphicRef116155" href="/z/d/graphic/116155.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma", section on 'Imaging'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intrahepatic cholangiocarcinoma – On cross-sectional imaging following contrast administration, there is peripheral (rim) enhancement throughout both arterial and venous phases. (See  <a class="medical medical_review" href="/z/d/html/2500.html" rel="external">"Clinical manifestations and diagnosis of cholangiocarcinoma", section on 'Imaging studies'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Liver metastases – The enhancement pattern of liver metastases varies depending on the primary malignancy. For example, metastatic liver lesions from the colon, stomach, and pancreas usually show lower attenuation (ie, are darker) in contrast to the brighter surrounding liver parenchyma on multiphasic CT of the liver  (<a class="graphic graphic_diagnosticimage graphicRef50064" href="/z/d/graphic/50064.html" rel="external">image 6</a>) [<a href="#rid21">21</a>]. Hypervascular metastases, such as those from neuroendocrine tumors, renal cell carcinoma, breast carcinoma, melanoma, and thyroid carcinoma, appear as rapidly enhancing lesions visible on the arterial phase of enhancement. (See  <a class="medical medical_review" href="/z/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring", section on 'Imaging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Growth pattern (if available) – For patients who have previous imaging available for comparison, absence of lesion growth over a one year time period suggests that the lesion is more likely to be benign [<a href="#rid22">22</a>].</p><p></p><p class="headingAnchor" id="H1723869990"><span class="h2">Initial evaluation</span><span class="headingEndMark"> — </span>For most patients with incidental liver lesions of uncertain etiology, the initial work up includes liver imaging (eg, contrast-enhanced, multiphasic, cross-sectional imaging [eg, magnetic resonance imaging (MRI)]) and identifying possible risk factors (eg, oral contraceptive use) [<a href="#rid1">1</a>]. If imaging fails to make the diagnosis, subsequent options include imaging surveillance or histologic evaluation (eg, biopsy or surgical resection).</p><p>For example, for female patients with suspected hepatocellular adenoma based on noncontrast ultrasound, the diagnosis is made with contrast-enhanced, cross-sectional imaging using MRI. (See  <a class="medical medical_review" href="/z/d/html/3590.html" rel="external">"Hepatocellular adenoma", section on 'Diagnostic approach'</a>.)</p><p class="headingAnchor" id="H188185847"><span class="h3">Is additional imaging warranted?</span><span class="headingEndMark"> — </span>For patients with incidental lesions but without risk factors for liver malignancy, the need for additional imaging depends on whether the lesion can be diagnosed based on the initial study. For example, the diagnosis of hepatic hemangioma can be made with noncontrast ultrasound if the following criteria are met (see  <a class="medical medical_review" href="/z/d/html/3594.html" rel="external">"Hepatic hemangioma", section on 'Diagnostic approach'</a>): </p><p class="bulletIndent1"><span class="glyph">●</span>Typical features are present (ie, homogenous, hyperechoic, well-delineated margin) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lesion size is &lt;3 cm</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient has no history of cirrhosis or extrahepatic malignancy</p><p></p><p>For lesions with a suspected diagnosis based on initial imaging study, further imaging is warranted to confirm the diagnosis. For example, if the diagnosis of hepatocellular adenoma is suspected based on ultrasound, the diagnosis can be made with a multiphase, contrast-enhanced MRI study.</p><p class="headingAnchor" id="H155744942"><span class="h3">Selecting an imaging modality</span><span class="headingEndMark"> — </span>Diagnostic imaging of solid liver lesions of uncertain etiology typically starts with contrast-enhanced, multiphasic, cross-sectional imaging. We typically use MRI; however, CT scan is an alternative if MRI is contraindicated or not available. (See  <a class="medical medical_review" href="/z/d/html/113084.html" rel="external">"Patient evaluation for metallic or electrical implants, devices, or foreign bodies before magnetic resonance imaging"</a>.) If the diagnosis remains uncertain after further imaging and the results will affect patient management, obtaining tissue for histologic examination (via biopsy or surgical resection) or surveillance imaging may be required. (See <a class="local">'Subsequent evaluation'</a> below.)</p><p>Typical imaging characteristics of solid liver lesions on noncontrast ultrasound, contrast-enhanced CT and MRI are listed here  (<a class="graphic graphic_table graphicRef127122" href="/z/d/graphic/127122.html" rel="external">table 1</a>). </p><p class="headingAnchor" id="H2733189408"><span class="h3">Specific imaging modalities</span></p><p class="headingAnchor" id="H3583929269"><span class="h4">Magnetic resonance imaging (MRI)</span><span class="headingEndMark"> — </span>MRI with multiphase enhancement of the liver can be performed using a gadolinium-based contrast agent (GBCA), while lesion intensity on T1- and T2-weighted images helps identify specific lesions [<a href="#rid23">23</a>]. While GBCA is well tolerated in most patients, it is associated with a small risk for nephrogenic systemic fibrosis or acute adverse reaction. These issues, along with patient evaluation before gadolinium administration, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">"Patient evaluation before gadolinium contrast administration for magnetic resonance imaging"</a>.)</p><p>Specific GBCAs for liver lesion examination include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9085" href="/z/d/drug information/9085.html" rel="external">Gadoxetate</a> disodium – Gadoxetate disodium, an MRI contrast agent that is slightly different from other gadolinium contrast, is typically used in this setting [<a href="#rid24">24</a>]. Gadoxetate is primarily taken up intracellularly by the hepatocytes and excreted in bile whereas other gadolinium contrast agents remain primarily extracellular and are excreted by the kidneys. This pharmacologic difference slightly alters the requirements for post-contrast imaging with gadoxetate. In addition to the image sets usually acquired for dynamic contrast administration, a hepatobiliary phase image set (usually 10 to 30 minutes after injection) is required. (See  <a class="medical medical_review" href="/z/d/html/5309.html" rel="external">"Principles of magnetic resonance imaging"</a>.) </p><p></p><p class="bulletIndent1">Thus, liver lesions that contain hepatocytes with an intact biliary excretion mechanism will take up this contrast agent and be easily distinguished from lesions that do not. Such lesions (eg, focal nodular hyperplasia  (<a class="graphic graphic_diagnosticimage graphicRef58438" href="/z/d/graphic/58438.html" rel="external">image 7</a>)), are typically benign and usually appear at least isointense to the liver parenchyma on delayed (two to three hours) post-contrast sequences.</p><p></p><p class="bulletIndent1">Lesion characteristics (eg, vascularity) that are visible on post-contrast, delayed images have contributed to imaging diagnostic accuracy. A study of 108 patients with confirmed focal nodular hyperplasia or hepatocellular adenoma (HCA) found that overall the sensitivity and specificity for contrast-enhanced MRI in differentiating focal nodular hyperplasia from HCA were 97 and 100 percent, respectively [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gadolinium ethoxybenzyl-diethylenetriamine pentaacetic acid – Gadolinium ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) is another GBCA that is taken up by hepatocytes and can be used to evaluate solid liver lesions [<a href="#rid26">26</a>]. Gd-EOB-DTPA is water-soluble, so it can be administered as a bolus injection. It can evaluate the enhancement characteristics and vascularity of liver lesions with a single-contrast injection. One area in which it has been used is the detection of hepatic metastases. Because metastatic lesions are not comprised of functional hepatocytes, they do not take up contrast and can be differentiated from the surrounding liver parenchyma [<a href="#rid27">27,28</a>]. </p><p></p><p class="headingAnchor" id="H1683548229"><span class="h4">Computed tomography (CT)</span><span class="headingEndMark"> — </span>Multiphase, contrast-enhanced CT (non-contrast, arterial, and portal venous phases) findings that help differentiate among lesions include the lesions' patterns of vascular enhancement and washout after contrast administration, the number of lesions, and associated findings in the liver [<a href="#rid1">1</a>]. For example, an enhancing solitary mass in a cirrhotic-appearing liver with portal vein thrombosis, ascites, and splenomegaly is suggestive of hepatocellular carcinoma, while a small peripheral-enhancing lesion in an asymptomatic female with an otherwise normal-appearing liver is suggestive of hepatic hemangioma  (<a class="graphic graphic_table graphicRef127122" href="/z/d/graphic/127122.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/3594.html" rel="external">"Hepatic hemangioma"</a>.) </p><p>While CT is widely available, it exposes patients to radiation, and this is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/14613.html" rel="external">"Radiation-related risks of imaging"</a>.)</p><p class="headingAnchor" id="H1793166962"><span class="h4">Ultrasonography</span><span class="headingEndMark"> — </span>Ultrasound is commonly performed as a noncontrast, transabdominal examination, but it can also be performed with contrast enhancement or intraoperatively:</p><p class="bulletIndent1"><span class="glyph">●</span>Noncontrast ultrasound – Characteristics on noncontrast ultrasound that may help with the diagnosis of a solid liver lesion include the lesion's echogenicity, the characteristics of the lesion's margins, the presence or absence of through-transmission, and findings on Doppler imaging [<a href="#rid29">29</a>]. Visualization may be difficult with lesions under the right hemidiaphragm, if there is overlying bowel gas, or in patients with obesity. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Contrast-enhanced ultrasound – Contrast-enhanced ultrasonography (CEUS) (where available) can be used to evaluate incidental liver lesions. Studies looking at CEUS for the characterization of focal liver lesions have estimated that CEUS has a sensitivity of approximately 95 percent and a specificity of approximately 94 percent for diagnosing malignancy [<a href="#rid30">30-34</a>]. </p><p></p><p class="bulletIndent1">Ultrasound contrast agents modify the basic physical interactions between ultrasound waves and body tissues and amplify the signal produced by flowing blood. These agents may be useful for detecting subtle flow abnormalities and for distinguishing areas of abnormal flow relative to normal background parenchymal perfusion. As a result, they may improve the characterization of liver lesions compared with noncontrast ultrasound. Contrast-enhanced ultrasonography has been used increasingly in some countries as a primary imaging modality for evaluation of patients with a liver lesion, and this is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/96352.html" rel="external">"Contrast-enhanced ultrasound for the evaluation of liver lesions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intraoperative ultrasonography – Intraoperative ultrasonography (during which the transducer is placed directly upon the liver surface) is the most sensitive imaging technique for diagnosing liver metastases [<a href="#rid35">35</a>]. As with other hepatic masses, intraoperative ultrasonography can be helpful in delineating the extent of disease and vascular landmarks during hepatic resection [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/z/d/html/88319.html" rel="external">"Open hepatic resection techniques", section on 'Staging laparoscopy and use of ultrasound'</a>.)</p><p></p><p class="headingAnchor" id="H2071374481"><span class="h2">Subsequent evaluation</span><span class="headingEndMark"> — </span>If the etiology of the liver lesion is uncertain after obtaining contrast-enhanced, cross-sectional imaging, options include imaging-guided biopsy, surgical resection, or surveillance imaging. </p><p class="headingAnchor" id="H3510692151"><span class="h3">Biopsy</span><span class="headingEndMark"> — </span>If the diagnosis is uncertain after obtaining contrast-enhanced, cross-sectional imaging, an imaging-guided biopsy can be performed if the results are likely to affect the patient's management [<a href="#rid37">37-41</a>]. However, a number of controversial issues surround the role of biopsy in this setting. First, it is often nondiagnostic when used to evaluate some types of liver lesions such as hepatocellular adenomas and focal nodular hyperplasia. Second, it is associated with some degree of risk, including bleeding and seeding of neoplastic cells [<a href="#rid42">42</a>]. For example, a biopsy is generally not performed in patients with suspected hepatocellular adenoma because of risk of hemorrhage, and this is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3590.html" rel="external">"Hepatocellular adenoma", section on 'Diagnostic approach'</a>.)</p><p>The use of liver biopsy for patients with suspected hepatocellular carcinoma is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma", section on 'Liver biopsy'</a>.)</p><p class="headingAnchor" id="H1056904927"><span class="h3">Surgical resection</span><span class="headingEndMark"> — </span>Surgical resection is rarely necessary for the establishing the diagnosis of an incidental solid liver lesion but may be performed for lesions of uncertain etiology that become symptomatic. If the diagnosis of HCC is suspected despite the absence of risk factors such as cirrhosis, surgical resection with histologic confirmation may be pursued if HCC cannot be excluded based on imaging. (See  <a class="medical medical_review" href="/z/d/html/2488.html" rel="external">"Surgical resection of hepatocellular carcinoma"</a>.)</p><p class="headingAnchor" id="H1950125625"><span class="h3">Surveillance imaging</span><span class="headingEndMark"> — </span>For incidental lesions that cannot be characterized with cross-sectional, contrast-enhanced imaging but are not amenable to biopsy (eg, lesions &lt;1 cm in size), surveillance imaging may be performed to detect lesion growth, changes in lesion appearance, and development of new lesions. Surveillance intervals are individualized depending on the suspected diagnosis and patient risk factors (eg, oral contraceptives) and generally range from 6 to 12 months. </p><p>Surveillance imaging for patients at risk for HCC is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma", section on 'Diagnostic approach'</a> and  <a class="medical medical_review" href="/z/d/html/3583.html" rel="external">"Surveillance for hepatocellular carcinoma in adults"</a>.)</p><p class="headingAnchor" id="H1362560949"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H3020573038"><span class="h2">Patients with extrahepatic malignancy</span><span class="headingEndMark"> — </span>Metastases to the liver are a potential cause of solid liver lesions in patients with a history of extrahepatic malignancy. In such patients, the evaluation begins with a search for metastatic disease in other organs. This typically involves computed tomography of the abdomen and pelvis as well as chest imaging. The presence of lesions in multiple organs supports a diagnosis of metastatic disease. The specific staging evaluation will depend on the primary malignancy. </p><p>Image-guided liver biopsy is often useful to confirm the diagnosis of metastatic disease [<a href="#rid43">43</a>]. However, histologic confirmation is not always essential if reasonable certainty can be achieved with imaging studies, or in settings in which there would be little benefit to the patient to confirm the diagnosis. </p><p>However, patients with extrahepatic malignancies may also have incidental liver lesions, so if the evaluation for metastatic disease suggests the lesion is not metastatic in origin, additional evaluation may be required (eg, surveillance imaging, particularly for lesions &lt;1 cm in size). (See <a class="local">'Surveillance imaging'</a> above.)</p><p class="headingAnchor" id="H618342294"><span class="h2">Patients with cirrhosis</span><span class="headingEndMark"> — </span>Patients with cirrhosis and some patients with chronic liver disease (eg, chronic hepatitis B virus infection) are at risk for developing hepatocellular carcinoma, and the approach to evaluating such patients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3583.html" rel="external">"Surveillance for hepatocellular carcinoma in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma"</a>.)</p><p class="headingAnchor" id="H899564444"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122574.html" rel="external">"Society guideline links: Focal liver lesions"</a>.)</p><p class="headingAnchor" id="H34"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background</strong> – Incidental liver lesions may be detected on imaging studies performed for an unrelated reason in adult patients without signs or symptoms (eg, right upper quadrant pain) attributable to the lesion. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1">The etiology of incidental liver lesions can be categorized as benign (eg, hepatic hemangioma, focal nodular hyperplasia) or malignant (eg, hepatocellular carcinoma). While most incidental lesions occur as a focal finding, multiple lesions may be seen in some patients (eg, those with more than one hepatic hemangioma). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic approach </strong>–<strong> </strong>As a first step in the diagnostic evaluation of an incidental liver lesion, it is important to confirm that the patient does not have risk factors for hepatocellular carcinoma (eg, cirrhosis, chronic hepatitis B virus infection) or for liver metastases (eg, history of extrahepatic malignancy)  (<a class="graphic graphic_algorithm graphicRef127404" href="/z/d/graphic/127404.html" rel="external">algorithm 1</a>). The diagnostic evaluation for patients who are at risk for developing a malignant liver lesion is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma"</a>.)</p><p></p><p class="bulletIndent1">For patients without risk factors for a malignant liver lesion, the initial diagnostic evaluation is primarily based on the imaging appearance of the incidental lesion. Lesion characteristics that guide further management include lesion size, appearance (eg, margin), enhancement pattern, and growth pattern. (See <a class="local">'Lesion characteristics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diagnostic imaging – Diagnostic imaging of solid liver lesions of uncertain etiology typically starts with contrast-enhanced, multiphasic, cross-sectional imaging. We typically use magnetic resonance imaging (MRI); however, computed tomography (CT) scan is an alternative if MRI is contraindicated or not available. (See  <a class="medical medical_review" href="/z/d/html/113084.html" rel="external">"Patient evaluation for metallic or electrical implants, devices, or foreign bodies before magnetic resonance imaging"</a> and <a class="local">'Selecting an imaging modality'</a> above.)</p><p></p><p class="bulletIndent2">MRI with multiphase enhancement of the liver can be performed using a gadolinium-based contrast agent (GBCA). (See <a class="local">'Magnetic resonance imaging (MRI)'</a> above.)</p><p></p><p class="bulletIndent2">While GBCA is well tolerated in most patients, it is associated with a small risk for nephrogenic systemic fibrosis or acute adverse reaction. These issues, along with patient evaluation before gadolinium administration, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">"Patient evaluation before gadolinium contrast administration for magnetic resonance imaging"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Subsequent testing – If the etiology of an incidental liver lesion is uncertain after obtaining contrast-enhanced cross-sectional imaging, subsequent options include imaging-guided biopsy, surgical resection, or surveillance imaging. (See <a class="local">'Subsequent evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with extrahepatic malignancy</strong> – For patients with a history of extrahepatic malignancy, liver metastases are a potential cause of solid liver lesions. In such patients, the evaluation begins with a search for metastatic disease in other organs (eg, CT of the abdomen and pelvis as well as chest imaging). The presence of lesions in multiple organs supports a diagnosis of metastatic disease, and the specific staging evaluation will depend on the primary malignancy. (See <a class="local">'Patients with extrahepatic malignancy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gore RM, Pickhardt PJ, Mortele KJ, et al. Management of Incidental Liver Lesions on CT: A White Paper of the ACR Incidental Findings Committee. J Am Coll Radiol 2017; 14:1429.</a></li><li><a class="nounderline abstract_t">Kelly ME, Heeney A, Redmond CE, et al. Incidental findings detected on emergency abdominal CT scans: a 1-year review. Abdom Imaging 2015; 40:1853.</a></li><li><a class="nounderline abstract_t">Nguyen XV, Davies L, Eastwood JD, Hoang JK. Extrapulmonary Findings and Malignancies in Participants Screened With Chest CT in the National Lung Screening Trial. J Am Coll Radiol 2017; 14:324.</a></li><li><a class="nounderline abstract_t">Bonder A, Afdhal N. Evaluation of liver lesions. Clin Liver Dis 2012; 16:271.</a></li><li><a class="nounderline abstract_t">Gandolfi L, Leo P, Solmi L, et al. Natural history of hepatic haemangiomas: clinical and ultrasound study. Gut 1991; 32:677.</a></li><li><a class="nounderline abstract_t">Farges O, Daradkeh S, Bismuth H. Cavernous hemangiomas of the liver: are there any indications for resection? World J Surg 1995; 19:19.</a></li><li><a class="nounderline abstract_t">European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the management of benign liver tumours. J Hepatol 2016; 65:386.</a></li><li><a class="nounderline abstract_t">Corallo C, Bell J, Laverty A, et al. Suspected focal nodular hyperplasia in male adults: 10-year experience from a large liver centre. Abdom Radiol (NY) 2023; 48:2292.</a></li><li><a class="nounderline abstract_t">González IA, Wang D, Pacheco MC, et al. Focal Nodular Hyperplasia in the Pediatric Population: A Multicenter Experience. Pediatr Dev Pathol 2023; 26:352.</a></li><li><a class="nounderline abstract_t">Kaltenbach TE, Engler P, Kratzer W, et al. Prevalence of benign focal liver lesions: ultrasound investigation of 45,319 hospital patients. Abdom Radiol (NY) 2016; 41:25.</a></li><li><a class="nounderline abstract_t">Horta G, López M, Dotte A, et al. [Benign focal liver lesions detected by computed tomography: Review of 1,184 examinations]. Rev Med Chil 2015; 143:197.</a></li><li><a class="nounderline abstract_t">International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995; 22:983.</a></li><li><a class="nounderline abstract_t">Furuya K, Nakamura M, Yamamoto Y, et al. Macroregenerative nodule of the liver. A clinicopathologic study of 345 autopsy cases of chronic liver disease. Cancer 1988; 61:99.</a></li><li><a class="nounderline abstract_t">Tsung A, Geller DA. Workup of the incidental liver lesion. Adv Surg 2005; 39:331.</a></li><li><a class="nounderline abstract_t">Schwartz LH, Gandras EJ, Colangelo SM, et al. Prevalence and importance of small hepatic lesions found at CT in patients with cancer. Radiology 1999; 210:71.</a></li><li><a class="nounderline abstract_t">Marrero JA, Ahn J, Rajender Reddy K, Americal College of Gastroenterology. ACG clinical guideline: the diagnosis and management of focal liver lesions. Am J Gastroenterol 2014; 109:1328.</a></li><li><a class="nounderline abstract_t">Yamashita Y, Ogata I, Urata J, Takahashi M. Cavernous hemangioma of the liver: pathologic correlation with dynamic CT findings. Radiology 1997; 203:121.</a></li><li><a class="nounderline abstract_t">Grazioli L, Federle MP, Brancatelli G, et al. Hepatic adenomas: imaging and pathologic findings. Radiographics 2001; 21:877.</a></li><li><a class="nounderline abstract_t">Mortelé KJ, Praet M, Van Vlierberghe H, et al. CT and MR imaging findings in focal nodular hyperplasia of the liver: radiologic-pathologic correlation. AJR Am J Roentgenol 2000; 175:687.</a></li><li><a class="nounderline abstract_t">Kehagias D, Moulopoulos L, Antoniou A, et al. Focal nodular hyperplasia: imaging findings. Eur Radiol 2001; 11:202.</a></li><li><a class="nounderline abstract_t">Ros PR, Davis GL. The incidental focal liver lesion: photon, proton, or needle? Hepatology 1998; 27:1183.</a></li><li><a class="nounderline abstract_t">Lamba R, Fananapazir G, Corwin MT, Khatri VP. Diagnostic imaging of hepatic lesions in adults. Surg Oncol Clin N Am 2014; 23:789.</a></li><li><a class="nounderline abstract_t">Grazioli L, Bondioni MP, Haradome H, et al. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology 2012; 262:520.</a></li><li><a class="nounderline abstract_t">Matos AP, Velloni F, Ramalho M, et al. Focal liver lesions: Practical magnetic resonance imaging approach. World J Hepatol 2015; 7:1987.</a></li><li><a class="nounderline abstract_t">Grazioli L, Morana G, Kirchin MA, Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005; 236:166.</a></li><li><a class="nounderline abstract_t">Haimerl M, Wächtler M, Zeman F, et al. Quantitative evaluation of enhancement patterns in focal solid liver lesions with Gd-EOB-DTPA-enhanced MRI. PLoS One 2014; 9:e100315.</a></li><li><a class="nounderline abstract_t">Zech CJ, Herrmann KA, Reiser MF, Schoenberg SO. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci 2007; 6:43.</a></li><li><a class="nounderline abstract_t">Van Beers BE, Pastor CM, Hussain HK. Primovist, Eovist: what to expect? J Hepatol 2012; 57:421.</a></li><li><a class="nounderline abstract_t">Assy N, Nasser G, Djibre A, et al. Characteristics of common solid liver lesions and recommendations for diagnostic workup. World J Gastroenterol 2009; 15:3217.</a></li><li><a class="nounderline abstract_t">Seitz K, Bernatik T, Strobel D, et al. Contrast-enhanced ultrasound (CEUS) for the characterization of focal liver lesions in clinical practice (DEGUM Multicenter Trial): CEUS vs. MRI--a prospective comparison in 269 patients. Ultraschall Med 2010; 31:492.</a></li><li><a class="nounderline abstract_t">Konopke R, Kersting S, Bergert H, et al. Contrast-enhanced ultrasonography to detect liver metastases : a prospective trial to compare transcutaneous unenhanced and contrast-enhanced ultrasonography in patients undergoing laparotomy. Int J Colorectal Dis 2007; 22:201.</a></li><li><a class="nounderline abstract_t">Trillaud H, Bruel JM, Valette PJ, et al. Characterization of focal liver lesions with SonoVue-enhanced sonography: international multicenter-study in comparison to CT and MRI. World J Gastroenterol 2009; 15:3748.</a></li><li><a class="nounderline abstract_t">Dietrich CF, Maddalena ME, Cui XW, et al. Liver tumor characterization--review of the literature. Ultraschall Med 2012; 33 Suppl 1:S3.</a></li><li><a class="nounderline abstract_t">Strobel D, Bernatik T, Blank W, et al. Diagnostic accuracy of CEUS in the differential diagnosis of small (≤ 20  mm) and subcentimetric (≤ 10  mm) focal liver lesions in comparison with histology. Results of the DEGUM multicenter trial. Ultraschall Med 2011; 32:593.</a></li><li><a class="nounderline abstract_t">Hagspiel KD, Neidl KF, Eichenberger AC, et al. Detection of liver metastases: comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative US, and percutaneous US. Radiology 1995; 196:471.</a></li><li><a class="nounderline abstract_t">Kruskal JB, Kane RA. Intraoperative ultrasonography of the liver. Crit Rev Diagn Imaging 1995; 36:175.</a></li><li><a class="nounderline abstract_t">Borzio M, Borzio F, Macchi R, et al. The evaluation of fine-needle procedures for the diagnosis of focal liver lesions in cirrhosis. J Hepatol 1994; 20:117.</a></li><li><a class="nounderline abstract_t">Fornari F, Filice C, Rapaccini GL, et al. Small (&lt; or = 3 cm) hepatic lesions. Results of sonographically guided fine-needle biopsy in 385 patients. Dig Dis Sci 1994; 39:2267.</a></li><li><a class="nounderline abstract_t">Limberg B, Höpker WW, Kommerell B. Histologic differential diagnosis of focal liver lesions by ultrasonically guided fine needle biopsy. Gut 1987; 28:237.</a></li><li><a class="nounderline abstract_t">Yu SC, Lau WY, Leung WT, et al. Percutaneous biopsy of small hepatic lesions using an 18 gauge automated needle. Br J Radiol 1998; 71:621.</a></li><li><a class="nounderline abstract_t">Tsou MH, Lin YM, Lin KJ, et al. Fine needle aspiration cytodiagnosis of liver tumors. Results obtained with Riu's stain. Acta Cytol 1998; 42:1359.</a></li><li><a class="nounderline abstract_t">Silva MA, Hegab B, Hyde C, et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008; 57:1592.</a></li><li class="breakAll">Saul SH. Masses of the liver. In: Diagnostic Surgical Pathology, 3rd ed, Sternberg SS (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 1999. p.1553.</li></ol></div><div id="topicVersionRevision">Topic 3575 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28927870" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Management of Incidental Liver Lesions on CT: A White Paper of the ACR Incidental Findings Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25576049" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Incidental findings detected on emergency abdominal CT scans: a 1-year review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28259326" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Extrapulmonary Findings and Malignancies in Participants Screened With Chest CT in the National Lung Screening Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22541698" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Evaluation of liver lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2060877" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Natural history of hepatic haemangiomas: clinical and ultrasound study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7740805" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cavernous hemangiomas of the liver: are there any indications for resection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27085809" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : EASL Clinical Practice Guidelines on the management of benign liver tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37043025" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Suspected focal nodular hyperplasia in male adults: 10-year experience from a large liver centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37082924" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Focal Nodular Hyperplasia in the Pediatric Population: A Multicenter Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26830608" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prevalence of benign focal liver lesions: ultrasound investigation of 45,319 hospital patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25860362" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : [Benign focal liver lesions detected by computed tomography: Review of 1,184 examinations].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7657307" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Terminology of nodular hepatocellular lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2825960" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Macroregenerative nodule of the liver. A clinicopathologic study of 345 autopsy cases of chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16250559" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Workup of the incidental liver lesion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9885589" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevalence and importance of small hepatic lesions found at CT in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25135008" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : ACG clinical guideline: the diagnosis and management of focal liver lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9122378" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cavernous hemangioma of the liver: pathologic correlation with dynamic CT findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11452062" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hepatic adenomas: imaging and pathologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10954451" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : CT and MR imaging findings in focal nodular hyperplasia of the liver: radiologic-pathologic correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11218015" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Focal nodular hyperplasia: imaging findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9581669" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The incidental focal liver lesion: photon, proton, or needle?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25246050" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Diagnostic imaging of hepatic lesions in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22282184" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26261689" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Focal liver lesions: Practical magnetic resonance imaging approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15955857" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24950259" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Quantitative evaluation of enhancement patterns in focal solid liver lesions with Gd-EOB-DTPA-enhanced MRI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17510541" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22504332" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Primovist, Eovist: what to expect?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19598296" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Characteristics of common solid liver lesions and recommendations for diagnostic workup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20652854" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Contrast-enhanced ultrasound (CEUS) for the characterization of focal liver lesions in clinical practice (DEGUM Multicenter Trial): CEUS vs. MRI--a prospective comparison in 269 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16733650" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Contrast-enhanced ultrasonography to detect liver metastases : a prospective trial to compare transcutaneous unenhanced and contrast-enhanced ultrasonography in patients undergoing laparotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19673015" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Characterization of focal liver lesions with SonoVue-enhanced sonography: international multicenter-study in comparison to CT and MRI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22723026" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Liver tumor characterization--review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22161556" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Diagnostic accuracy of CEUS in the differential diagnosis of small (≤ 20 mm) and subcentimetric (≤ 10 mm) focal liver lesions in comparison with histology. Results of the DEGUM multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7617863" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Detection of liver metastases: comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative US, and percutaneous US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7546269" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Intraoperative ultrasonography of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8201212" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The evaluation of fine-needle procedures for the diagnosis of focal liver lesions in cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7924754" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Small (&lt;or = 3 cm) hepatic lesions. Results of sonographically guided fine-needle biopsy in 385 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3552904" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Histologic differential diagnosis of focal liver lesions by ultrasonically guided fine needle biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9849384" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Percutaneous biopsy of small hepatic lesions using an 18 gauge automated needle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9850643" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Fine needle aspiration cytodiagnosis of liver tumors. Results obtained with Riu's stain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18669577" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
